This article summarized the latest R&D progress of Raloxifene Hydrochloride, the Mechanism of Action for Raloxifene Hydrochloride, and the drug target R&D trends for Raloxifene Hydrochloride.
The recent ESMO Congress presented noteworthy clinical trial results of Givastomig, paving the way for a detailed exploration of its therapeutic potential in solid tumors.
A ketoreductase enzyme has undergone a gene mutation at a certain mutation site and has acquired a mutant enzyme with higher activity. How can one search for publicly available sequences of such enzyme mutants, as well as other popular mutation sites?
Small-molecule CDK2 selective inhibitors would be significant chemical probes for dissecting cellular processes or understanding the basics of diseases.
On 23 Oct 2023, GALLANT-1: GB1211 galectin-3 (Gal-3) inhibitor plus atezolizumab (atz) for first line treatment in patients (pts) with advanced/metastatic non-small cell lung cancer (NSCLC) was reported at the ESMO Congress.
This article summarized the latest R&D progress of Retapamulin, the mechanism of action for Retapamulin, and the drug target R&D trends for Retapamulin.
On 23 Oct 2023, the phase Ib/II clinical trial result of Cadonilimab combined with lenvatinib for first-line treatment of advanced hepatocellular carcinoma was reported at the ESMO Congress.
Monte Rosa Therapeutics unveils preclinical findings. The research indicates that MRT-6160, a VAV1-specific molecular glue breaker, may be effective in treating immune-based and inflammatory disorders.
Calcineurin inhibitors, acting as immunosuppressive agents, are employed in the treatment of autoimmune disorders like lupus nephritis, atopic dermatitis, interstitial lung disease, and idiopathic inflammatory myositis, among others.